implications but also for the appropriate management of the patient.
On the other hand, epidemiological data are scarce when it comes to the incidence and outcome of AKI among hospitalized AHF patients classified according to their left ventricular ejection fraction (EF). In 2013, the American College of Cardiology Foundation/American Heart Association (ACC/AHA) introduced heart failure (HF) with borderline EF (range, 40% to 50%) as a subcategory of HF with preserved EF. 5 In 2016, the European Society of Cardiology (ESC) went further and classified HF with mid -range EF (HFmrEF) as a distinct category in their guidelines. 6 While the importance of comparing comorbidities and assessing risks for HFmrEF patients INTRODUCTION Cardiorenal syndrome (CRS) is a complex pathophysiologic disorder that describes the hemodynamic and neurohormonal interaction between the heart and kidney, whereby acute dysfunction in one organ leads to acute dysfunction in the other. 1 Acute kidney injury (AKI) is recognized to be an independent predictor of poor short-and long -term outcome in patients with acute decompensated heart failure (ADHF) due to fluid overload or low output, 2 although an aggressive decongestive therapy has been identified as having a positive effect on survival. 3 Renal function worsening has also been well described for patients with acute heart failure (AHF) admitted to intensive care units, 4 as its recognition is important not only for its clinical ORIGINAL ARTICLE Acute kidney injury: a clinical issue in hospitalized patients with heart failure with mid -range ejection fraction with more than a 2 -fold increase in serum creatinine levels from baseline (ie, describing greater renal injury), we agreed to focus on AKI diagnosis itself rather than to grade the condition.
Admission creatinine level was taken as the baseline. Each EF group was further divided into subgroups based on the presence of AKI. Comparisons were made between the resulting groups.
For AKI patients, the CRS was considered as type 1 in those with unknown kidney disease, type 2 in those with known chronic heart failure, and type 4 in those with known chronic kidney disease. 12 Information on medication at admission and during hospitalization was obtained from data sheets, and medication use was evaluated as risk factors for AKI development: angiotensin -converting enzyme inhibitors / adrenergic angiotensin receptor blockers, spironolactone, and furosemide, including a cumulative diuretic dose.
Data analysis Descriptive statistics included the observed frequency counts (percentage) for categorical variables and median (interquartile range) for numerical variables. Categorical variables were compared with the χ 2 test (either asymptotic or Monte Carlo simulation with 10 000 replicates) or the Fisher exact test. For a stratified analysis of categorical variables, the Mantel-Haenszel test was employed. Odds ratios (ORs) were used as risk estimates. The distribution of numerical variables across multiple groups was compared with the Kruskal-Wallis test.
Survival analysis was conducted to investigate the AKI -associated death among the 3 EF ranges, observing the Kaplan-Meier curves and applying the log -rank test. For survival time, the mean and standard error were used as descriptive statistics. To calculate the HRs, the Cox proportional hazards model was used, starting with crude models and further controlling for possible confounders related to age and sex, or associated comorbidities significant in a univariate analysis (the latter finally discarded in the analysis). The proportional hazards assumptions were evaluated using both graphic and goodness -of -fit approaches (ie, both log -log plots and correlation testing for the Schoenfeld residuals to ranked failure times). The regression models were compared using likelihood ratio statistic and the χ 2 test.
All reported probability values were 2 -tailed, and the significance levels of 0.05 and 0.01 were assumed as denoting significant and highly significant results, respectively. Statistical analysis was conducted with SPSS v.20 and R v.3.2.3 software packages (https://www.r -project.org/; including "survival" and "powerSurvEpi" packages).
Ethical standards
The study was approved by the Committee for Medical Research Ethics of Arad County Emergency Clinical Hospital. Patients were not required to give informed consent, because the analysis was conducted is acknowledged, 7-10 specific evidence and data on its subsequent application in everyday clinical practice are still limited.
This study aimed at evaluating the mortality prognosis of AKI in hospitalized patients with ADHF grouped according to their EF, with a focus on the HFmrEF condition.
PATIENTS AND METHODS Study design and population
A retrospective cross -sectional study on routinely collected medical data was conducted, including 365 consecutive patients admitted to the Cardiology Unit of Arad Emergency Clinical County Hospital, between July 2012 and December 2016, with a primary diagnosis of ADHF. Collected data were de -identified before conducting the statistical analysis and no written informed consent was needed for this secondary use of medical data. Included health records were reviewed and HF was diagnosed based on Framingham criteria.
The primary focus was on AKI among patients with HFmrEF, so we decided to estimate the necessary sample size for this group, and it resulted in a total of 142 patients (for hazard ratio [HR], 2; proportion of AKI -exposed patients, 0.3; baseline event rate, 0.06; average planned length of in -hospital follow -up, 21 days; median survival time, 11 days; censoring rate, 0.05; α = 0.05; and β = 0.2). All consecutive patients who met the criterion for ADHF diagnosis were included (starting with December 2016 and going backwards in medical records archives). The only exclusion criteria were prior renal replacement therapy and active cancer. ADHF patients were evaluated as 3 separate groups, based on their left ventricular EF and according to the 2016 ESC guidelines on HF 6 : HFpEF (≥50%), HFmrEF (40%-49%), and HFrEF (≤40%). Overall data accrual stopped when the planned number for the HFm-rEF group was attained. For each patient, data from medical records referring to the current episode of care were collected (ie, from hospital admission to discharge or death), including age, sex, New York Heart Association class, comorbidities, electrocardiographic parameters, laboratory data, and EF measured by cardiac ultrasonography (Simpson biplane method) were recorded.
AKI was evaluated based on Acute Kidney Injury Network (AKIN) criteria, 11 defined as an abrupt increase in serum creatinine levels (0.3 mg/dl within 48 h) and a percentage increase in serum creatinine levels of 50% or higher (1.5 -fold increase from baseline). The AKIN criteria were chosen owing to their higher sensitivity in identifying patients with AKI compared with the RIFLE criteria, based on a meta--analysis of Xiong et al, 12 and their higher specificity for predicting primary outcomes at 30 days in ADHF patients, thus resulting in better positive predictive values in the short term. 13 Furthermore, due to the small number of patients differences regarding the medication use between the AKI subgroups. The results of medical investigations and the medication use prior to and during the current episode of care are shown in TABLE 2.
For exploratory purposes, in TABLES 1 and 2, the statistical tests were first conducted across the 6 groups of AKI -EF combinations (a comparison of AKI vs non-AKI groups for each EF category would have unnecessarily inflated the risk of type 1 statistical error). When the test across the 6 groups was statistically significant, further testing was carried out for each AKI/non-AKI condition across the 3 EF groups.
Acute kidney injury and in -hospital mortality risk
A total of 40 in -hospital deaths (10.96%) were recorded. The risk analysis for AKI -associated mortality in the 3 EF groups is shown in TABLE 3. There was no association in the HFpEF group, while the ORs for the other 2 groups were high and significant. The risk in the HFmrEF group was higher (with a significant difference between the 2 EF categories, as demonstrated by the Mantel-Haenszel test).
retrospectively on de -identified medical data and each patient had agreed to treatment by written consent.
RESULTS Baseline characteristics
The mean (SD) age of the study population was 68.56 (10.59) years, of which 44% were female. Of the total 365 patients, 66 (18.1%), 142 (38.9%), and 157 (43%) had HFpEF, HFm-rEF, and HFrEF, respectively. AKI was diagnosed in 99 patients with ADHF (27.1%): 16 patients with HFpEF (4.4%), 37 patients with HFmrEF (10.1%), and 46 patients with HFrEF (12.6%). AKI patients in the HFmrEF group showed a higher prevalence of chronic kidney disease (CKD) than AKI patients in the HFrEF and HF-pEF groups (64.9% vs 58.7% and 50%, respectively; P = 0.001). Chronic obstructive pulmonary disease was frequent in AKI patients with HFpEF, and valvular heart disease, in AKI patients with HFrEF. The detailed baseline characteristics are presented in TABLE 1.
The HFrEF -AKI group also had the worst kidney function, expressed as glomerular filtration rate (P <0.001). There were no significant Data are presented as median (IQR), with the Kruskal-Wallis test applied to compare distributions across the 6 groups of AKI -EF combination, or as number (percentage) of patients, with the χ 2 test (either asymptotic or Monte -Carlo simulation with 10 000 samples) applied to investigate the significance of observed differences in proportions. P <0.05 and P <0.01 were considered significant and highly significant, respectively.
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRS, cardiorenal syndrome; EF, ejection fraction; HD, heart disease; HFmrEF, heart failure with mid -range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; NYHA, New York Heart Association 1A-1C . The Cox proportional hazards regression analysis (TABLE 5) was conducted for the 2 EF groups that showed the association of AKI with a higher Acute kidney injury-associated mortality hazard ratio for acute decompensated heart failure patients with mid -range ejection fraction The survival analysis of AKI -associated mortality for the 3 EF groups is presented in TABLE 4. It shows a highly significant shortening of the survival time for the AKI subgroups both in the HFmrEF and HFrEF groups. The overall median survival time was 45 days Data are presented as median (IQR) a,b or as number (percentage) d . P <0.05 and P <0.01 were considered significant and highly significant, respectively.
a The Kruskal-Wallis test was applied to compare distributions across the 6 groups of AKI -EF combination.
b
The Kruskal-Wallis test was applied to compare distributions across the 3 EF groups for no -AKI and AKI subgroups, respectively (P values are specified for the 2 subgroups)
c Difference between serum creatinine levels at admission and at 48 hours since admission.
d The χ 2 test (asymptotic or Monte -Carlo simulation with 10 000 samples) was applied to investigate the significance of observed differences in proportions between the 6 groups of AKI -EF combination.
Abbreviations: ACEI, angiotensin -converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; EF, ejection fraction; GFR, glomerular filtration rate; K, potassium; hosp., diagnosed or prescribed during hospital stay, during the current episode of care; MRA, mineralocorticoid antagonist; Na, sodium; NA, not applicable; prev., previously diagnosed or prescribed, before the current episode of care; others, see change within the first 48 hours from admission in order to minimize this possible issue and study patients at risk due to AHF. While the overall percentage of deaths was higher among HFrEF patients, the AKI -associated in -hospital mortality risk resulted in an almost twice higher OR for HFmrEF patients than for HFrEF patients. This suggests a stronger impact of AKI on the clinical evolution in the HFmrEF group. Though Kapoor et al 24 reported worsening renal failure as an independent risk factor for in -hospital mortality in patients with HF irrespective of EF, the present results partially confirm previously reported risk values for in -hospital mortality associated with AKI in AHF patients, 15,25-27 also bringing new information for each range of left ventricular EF.
Acute kidney injury-associated mortality hazard ratio for acute decompensated heart failure patients with mid -range ejection fraction Not surprisingly, AKI proved to be a highly significant discriminatory factor in the survival analysis for both HFmrEF and HFrEF patients. According to Nauta et al, 28 there is a high resemblance between HFmrEF and HFrEF with respect to ischemic etiology, biomarkers, and response to treatment. Ronco et al 29 showed that, in AHF, AKI might be a consequence of both backward failure (due to increased intra -abdominal and central venous number of events and decreased survival time (log -rank test, P <0.05): HFmrEF and HFrEF.
DISCUSSION Acute kidney injury and in -hospital
mortality risk Though different classification criteria are being used in medical practice, comparing results across the studies is of great interest. Roy et al 13 considered and discussed the pros and cons of AKI definitions and rankings, with the ensuing consequences, concluding that the differences in terms of predictive abilities were only marginal. Therefore, we compared the results to other studies on ADHF patients, irrespective of their classification system, and found that AKI incidence at admission was similar 14-16 : 24%, 26%, and 29% for HFpEF, HFmrEF, and HFrEF, respectively. On the other hand, the overall proportion of HFpEF patients in this study was unusually small when compared to larger -size, registry--based studies. 17, 18 We observed a higher proportion of acute worsening of renal function in patients with HFmrEF and pre -existing CKD. Zhou et al 19 already reported the pre -existing CKD as a risk factor for AKI in ADHF patients, and Yamigishi et al 20 demonstrated that a history of hypertension was a risk factor for AKI in ADHF patients. Considering that additional studies reported acute worsening of renal function during hospitalization, 18,21-23 we focused on the creatinine Overall comparison adjusted for the HF group: log -rank test, χ 2 = 14 588 (df = 1); P <0.001 was considered highly significant.
Abbreviations: see TABLES 1 and 3 b The proportional hazards assumptions were evaluated and were met. P <0.001 was considered highly significant.
Abbreviations: HR, hazard ratio; LR, likelihood ratio; others, see TABLES 1 and 3
FIGURE 1
Kaplan-Meier curves for in -hospital mortality associated with acute kidney injury in hospitalized patients with heart failure with preserved ejection fraction (EF) (A), mid--range EF (B); and reduced EF (C) Conclusions This pilot study provides novel insights into renal injury in the AHF setting, while considering the newly proposed classification for left ventricular EF. HFmrEF is an emerging category from the previously recognized HF classifications, and it seems to have distinct characteristics with serious survival impact on hospitalized patients. Though larger studies are needed to explore the mechanisms and strategies to distinguish the primary origin of kidney injury in these ADHF populations and develop evidence -based therapies, the present study proved that AKI is significantly associated with a higher risk of mortality in patients with HFmrEF when compared with those with HFrEF, thus implying a stronger impact of AKI on their outcome. ACKNOWLEDGMENTS This research did not receive any grant from funding agencies in the public, commercial, or not -for -profit sectors.
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OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 4.0 International License (CC BY -NC -SA 4.0), allowing third parties to copy and redistribute pressure, thus indicating CRS type 2) and forward failure (low output state indicating CRS type 1), combined with neurohormonal activation, hypothalamic -pituitary stress reaction, and inflammation. The Cox regression analysis conducted in the present study provided evidence that an AKI -associated HR for HFmrEF was even higher than for HFrEF.
Strengths and limitations
The main strength of this pilot study consists in evaluation of the AKI association with mortality risk in ADHF patients, while considering the 3 EF ranges according to recent ESC and ACC/AHA guidelines. An important limitation is the retrospective cross -sectional observational design, as it is unable to distinguish antecedent from consequent in clinical conditions and to calculate population -based rates, the latter shortcoming leading to a sample size discrepancy between the HFpEF and the other 2 EF groups. This difference might be explained by the fact that HF-pEF patients had been earlier discharged from the emergency room after having received decongestive therapy, so no data were available in the reviewed medical records. Due to limited information in medical records, the differentiation between CRS type 2 and 4 was also challenging. An additional limitation is the retrospective design: the medical decision was based mainly on the clinical signs (ie, serum biomarkers not available for all cases) and the baseline AKI diagnosis was solely made at admission (ie, no reassessment during hospitalization and no severity grading). the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.
